SCHEMBL13170709

SCHEMBL13170709

N#Cc1ccc(-c2ccc(-c3ccc4cc(-c5ccc6c7c(cccc57)-c5c-6c(-c6ccccc6)c6ccccc6c5-c5ccccc5)ccc4c3)cc2)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
PIM1 P11309 2/20 0.38
PDK2 Q15119 1/20 0.38
KAT6A Q92794 1/20 0.37
HRH3 Q9Y5N1 4/20 0.36
PRKDC P78527 1/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
GABRA5 P31644 1/20 0.36
GABRA3 P34903 1/20 0.36
PGR P06401 1/20 0.36
ALDH1A1 P00352 2/20 0.35
ATM Q13315 1/20 0.35
SLC22A12 Q96S37 1/20 0.35
BCL2 P10415 1/20 0.35
MCL1 Q07820 1/20 0.35
ABCB1 P08183 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3218300 1.00 CYP17A1 (0.39) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170712 0.99 PRKDC (0.38) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL21249213 0.98 PIM1 (0.41) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170660 0.98 CYP17A1 (0.39) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170716 0.96 PIM1 (0.37) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170681 0.95 ESR1 (0.38) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170711 0.95 CYP11B1 (0.44) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13192361 0.95 PIM1 (0.38) CYP17A1CYP11B1CYP11B2PIM1GABRA1
SCHEMBL21467599 0.94 CYP17A1 (0.36) CYP17A1CYP11B1CYP11B2PIM1PDK2
SCHEMBL13170653 0.94 CYP11B1 (0.43) CYP17A1CYP11B1CYP11B2PIM1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512137-B2 Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2016-12-06 US disclosed
US-9512137-B2 Organic electroluminescence device IDEMITSU KOSAN CO., LTD. (JP) 2016-12-06 US disclosed
US-20120256172-A1 ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2012-10-11 US disclosed
US-20120256172-A1 ORGANIC ELECTROLUMINESCENCE DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2012-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120256172-A1 ORGANIC ELECTROLUMINESCENCE DEVICE SLC25A21, SLC25A11, SLCO4C1 CYP17A1 2851/4885CYP11B1 2077/4885CYP11B2 1935/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.